Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 2-Fluoro-ARA-AMP; Beneflur; Fludara; Fludarabine phosphate; NSC 312887

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Southern Research Institute
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Sanofi; Sanofi Genzyme
  • Class Antineoplastics; Arabinonucleosides; Myeloablative agonists; Purine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2016 Genzyme completes a phase I/II trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Spain (IV) (NCT01435343)
  • 06 Aug 2014 Fludarabine licensed to Emcure Pharmaceuticals in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top